Gilead's hep C combo Harvoni hoves into EU view
This article was originally published in Scrip
Executive Summary
Gilead's highly anticipated fixed-dose combination hepatitis C therapy Harvoni (sofosbuvir/ledipasvir 400 mg / 90 mg, film coated tablet) is one step closer to the EU market following a positive opinion from the EU's CHMP.